Semaglutide for post-liver transplant obesity
- Conditions
- ObesityMetabolic syndromeLiver transplantDiet and Nutrition - ObesityOral and Gastrointestinal - Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colonSurgery - Other surgery
- Registration Number
- ACTRN12621001739808
- Lead Sponsor
- Austin Health
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot yet recruiting
- Sex
- All
- Target Recruitment
- 100
Patients who have undergone liver transplant between 6 months and 5 years prior to enrolment with:
•BMI >30
•BMI >27 in conjunction with any additional risk factor for metabolic disease (index liver transplant for NAFLD, diabetes mellitus, hyperlipidemia, personal or first degree family history of coronary artery disease, HTN or past or active smoking status)
•Active cancer
•Active infection
•Frailty (hand grip strength <2 standard deviations below the age and gender-specified mean)
•Age <18 years or >70 years
•Prior pancreatitis
•Previous bariatric surgery
•Use of anti-obesity medication 90 days before enrollment
•Use of GLP-1 analogue 90 days before enrollment
•Stage 4 chronic kidney disease (eGFR <30mL/min)
•Symptomatic New York Heart Association stage III or IV heart failure
•Child Pugh B or C cirrhosis
•Unable to provide consent
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Proportion of patients achieving at least 5% body weight loss, measured on calibrated weighing scales [Body weight will be measured at baseline, week 4, week 12, week 42, week 56 and week 68 post commencement of intervention. Week 68 is the primary timepoint. ];Percentage change in body weight, measured on calibrated weighing scales[Body weight will be measured at baseline, week 4, week 12, week 42, week 56 and week 68 post commencement of intervention. Week 68 is the primary timepoint]
- Secondary Outcome Measures
Name Time Method